Global OTC leader grows in China
This article was originally published in The Tan Sheet
Executive SummaryJapanese firm Taisho Pharmaceutical, an OTC manufacturer and a majority stakeholder of Chinese firm Shanghai Dazhengli Health Care, purchased the 15 percent of the firm held by the Guan Shen Yuan Group for 14.7994 million yuan ($2.2 million at Sept. 24 conversion rates). Taisho set up Shanghai Dazhengli Health Care in 1997 to sell its Libogen products in China. Shanghai Dazhengli can produce more than 20 million bottles of Lipovitan D nutrient drink annually. Taisho wants to expand its production and sales in China from Shanghai
You may also be interested in...
For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.